Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)

Description

This research is being done to better understand rejection in transplant recipients with HIV who receive kidneys from donors with vs without HIV.

Conditions

Hiv

Talk to us

Study Overview

On this page

Study Details

Study overview

This research is being done to better understand rejection in transplant recipients with HIV who receive kidneys from donors with vs without HIV.

HOPE in Action Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes

Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)

Condition
Hiv
Intervention / Treatment

-

Contacts and Locations

Birmingham

University of Alabama at Birmingham, Birmingham, Alabama, United States, 35294

Los Angeles

University of California, Los Angeles, Los Angeles, California, United States, 90095

San Diego

University of California, San Diego, San Diego, California, United States, 92037

San Francisco

University of California, San Francisco, San Francisco, California, United States, 94143

Chicago

Rush University Medical Center, Chicago, Illinois, United States, 60612

New Orleans

Ochsner Clinic Foundation, New Orleans, Louisiana, United States, 70121

Baltimore

Johns Hopkins University, Baltimore, Maryland, United States, 21205

Boston

Massachusetts General Hospital, Boston, Massachusetts, United States, 02114

New York

New York University, New York, New York, United States, 10016

New York

Icahn School of Medicine at Mt. Sinai, New York, New York, United States, 10029

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participant meets local criteria for kidney transplant.
  • * Participant is able to understand and provide informed consent.
  • * Participant has documented HIV infection by any licensed assay or documented history of detectable HIV-1 RNA.
  • * Participant is ≥ 18 years old.
  • * Cluster of differentiation 4 (CD4+) T-cell count: ≥ 200/μL within 16 weeks of transplant.
  • * HIV-1 RNA \< 50 copies/mL. Viral blips between 50-400 copies will be allowed as long as there are not consecutive measurements \> 200 copies/mL.
  • * Participant is not suffering from significant wasting (e.g. body mass index \<21) thought to be related to HIV disease.
  • * Participant meets with an independent advocate.
  • * Participant has prior progressive multifocal leukoencephalopathy (PML), cryptosporidiosis of \> 1 month, or primary central nervous system (CNS) lymphoma.
  • * Participant is pregnant or breastfeeding.
  • * Past or current medical problems or findings from medical history, physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Johns Hopkins University,

Christine Durand, MD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

2029-09